Axaitech is building the next generation of liquid biopsy multi-cancer early-detection tests using uniquely African datasets for enhanced precision and reduced clinical bias. Liquid Biopsy Multi-cancer early detection allows for an increased patient survival rate of up to 300%. With 57% of the world’s cancer burden in Africa, Axaitech was founded as Africa's answer to the global liquid biopsy movement in cancer diagnosis and treatment.
Students worked to develop data-driven machine learning models that would predict certain types of cancer occurring in individuals based on their individual blood biomarkers.
